FDA Approves MORPHINE SULFATE — SpecGx LLC

# FDA Approves SpecGx LLC's Generic Morphine Sulfate Oral Formulation SpecGx LLC has received FDA approval for its generic morphine sulfate oral formulation (ANDA202348), expanding the competitive landscape in the opioid pain management market and providing patients with a more affordable alternative to branded versions. The approval is expected to increase generic competition in the oral morphine segment, potentially reducing costs for healthcare systems and patients while broadening SpecGx's portfolio in the pain management category.